Tango Therapeutics Inc. (TNGX)
TNGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/0001193125-26-092518-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TNGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001819133 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $62.4M |
| Net income | -$101.6M |
| Operating income | -$111.3M |
| Net margin | -162.9% |
| Operating margin | -178.4% |
| Revenue growth | +48.3% |
| Cash | $112.3M |
| Total assets | $398.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 65.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $86.8M cash; operating cash flow -$37.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 169,455,160 (2026-11-02); 134,593,998 a year earlier; 88,467,269 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-08-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $11.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$68.4M | -$37.1M | $86.8M | No debt tags | $0 | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $0 | -$55.3M | -$38.9M | $345.6M | No debt tags | $53.8M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $0 | -$45.5M | -$44.4M | $157.8M | No debt tags | $57.0M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $0 | -$38.7M | -$29.7M | $112.3M | No debt tags | $62.4M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $53.8M | $15.9M | -$31.0M | $58.3M | No debt tags | $66.5M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $3.2M | -$38.9M | -$36.5M | $58.3M | No debt tags | $24.3M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $5.4M | -$39.9M | -$41.7M | $58.4M | No debt tags | $41.0M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $4.1M | -$37.7M | -$36.6M | $69.5M | No debt tags | $42.1M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-11 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 430 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.6% |
| 1 month | +14.8% |
| 3 months | -0.6% |
| Year to date | +187.8% |
| 1 year | +230.3% |
| From 52-week high | -22.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $39.26 | -3.01% | $3.9B |
| OGN | Organon & Co. Common Stock | $13.90 | 0.00% | $3.7B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier